CN1020944C
(zh)
*
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
US6515117B2
(en)
*
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
FR2809310B1
(fr)
*
|
2000-05-26 |
2004-02-13 |
Centre Nat Rech Scient |
Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
|
US20020082222A1
(en)
|
2000-11-30 |
2002-06-27 |
Shapira Nathan Andrew |
Treatments for neurogenetic disorders, impulse control disorder, and wound healing
|
PT1953162E
(pt)
*
|
2001-02-24 |
2012-07-13 |
Boehringer Ingelheim Pharma |
Derivados de xantina, sua preparação e sua utilização como produto farmacêutico
|
US6936590B2
(en)
*
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
EP2065044A1
(fr)
*
|
2001-04-04 |
2009-06-03 |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. |
Polythérapie comprenant des inhibiteurs de la réabsorption du glucose et des modulateurs PPAR
|
DK1385856T3
(da)
*
|
2001-04-11 |
2006-05-15 |
Bristol Myers Squibb Co |
Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
|
US20030087843A1
(en)
*
|
2001-09-05 |
2003-05-08 |
Washburn William N. |
O-pyrazole glucoside SGLT2 inhibitors and method of use
|
TWI254635B
(en)
*
|
2002-08-05 |
2006-05-11 |
Yamanouchi Pharma Co Ltd |
Azulene derivative and salt thereof
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
EP1550668A4
(fr)
*
|
2002-10-04 |
2008-10-01 |
Kissei Pharmaceutical |
Derive de pyrazole, composition medicinale renfermant ce derive, utilisation medicinale de cette composition, et intermediaire entrant dans sa production
|
DE10258007B4
(de)
*
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
BR0317929A
(pt)
*
|
2003-01-03 |
2006-04-11 |
Bristol Myers Squibb Co |
métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
|
EP1457206A1
(fr)
*
|
2003-03-13 |
2004-09-15 |
Fournier Laboratories Ireland Limited |
Utilisation combinée d'un fibrate et de l'orlistat pour le traitement de l'obésité
|
WO2004080990A1
(fr)
|
2003-03-14 |
2004-09-23 |
Astellas Pharma Inc. |
Derives de c-glycoside et sels correspondants
|
JP2004300102A
(ja)
*
|
2003-03-31 |
2004-10-28 |
Kissei Pharmaceut Co Ltd |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
CA2549025A1
(fr)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Indole-o-glucosides substitues
|
AR048376A1
(es)
*
|
2003-08-01 |
2006-04-26 |
Janssen Pharmaceutica Nv |
C- glicosidos heterociclos fusionados sustituidos
|
SI2896397T2
(sl)
|
2003-08-01 |
2020-12-31 |
Mitsubishi Tanabe Pharma Corporation |
Nove spojine z inhibicijsko aktivnostjo proti od natrija odvisnemu glukoznemu transporterju
|
EA011515B1
(ru)
*
|
2003-08-01 |
2009-04-28 |
Янссен Фармацевтика Н.В. |
Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
|
EA010655B1
(ru)
*
|
2003-08-01 |
2008-10-30 |
Янссен Фармацевтика Н.В. |
Замещенные индазол-о-глюкозиды
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
WO2005085265A1
(fr)
*
|
2004-03-04 |
2005-09-15 |
Kissei Pharmaceutical Co., Ltd. |
Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse
|
EP2295422A3
(fr)
*
|
2004-03-16 |
2012-01-04 |
Boehringer Ingelheim International GmbH |
Dérivés de benzol substitués par glucopyranosyl, médicament contenant ces composés, leur utilisation et leur procédé de fabrication
|
ATE493973T1
(de)
|
2004-06-04 |
2011-01-15 |
Teva Pharma |
Irbesartan enthaltende pharmazeutische zusammensetzung
|
US7393836B2
(en)
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
DE102004034690A1
(de)
*
|
2004-07-17 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
TW200606129A
(en)
*
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
JP2008508213A
(ja)
*
|
2004-07-27 |
2008-03-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
D−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
JP5046370B2
(ja)
*
|
2004-09-29 |
2012-10-10 |
キッセイ薬品工業株式会社 |
1−(β−D−グリコピラノシル)−3−置換含窒素ヘテロ環化合物、それを含有する医薬組成物及びその医薬用途
|
DE102004048388A1
(de)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US20090036355A1
(en)
*
|
2004-10-13 |
2009-02-05 |
Sanjay Bhanot |
Antisense Modulation of PTP1B Expression
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
JP2008524162A
(ja)
*
|
2004-12-16 |
2008-07-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
MY147375A
(en)
*
|
2005-01-31 |
2012-11-30 |
Mitsubishi Tanabe Pharma Corp |
Indole derivatives
|
AR053329A1
(es)
*
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
DE602006004964D1
(de)
*
|
2005-02-10 |
2009-03-12 |
Bristol Myers Squibb Co |
Dihydrochinazolinone als 5ht-modulatoren
|
DE602006009772D1
(de)
*
|
2005-02-23 |
2009-11-26 |
Boehringer Ingelheim Int |
Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
|
ES2338041T3
(es)
*
|
2005-04-15 |
2010-05-03 |
Boehringer Ingelheim International Gmbh |
Derivados de (heteroariloxi-bencil)-benceno sustituidos con glucopiranosilo en calidad de inhibidores de sglt.
|
US7723309B2
(en)
*
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7772191B2
(en)
*
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
WO2007000445A1
(fr)
*
|
2005-06-29 |
2007-01-04 |
Boehringer Ingelheim International Gmbh |
Derives de benzyle-benzene a substitution glucopyranosyle, medicaments contenant de tels composes, utilisation et production de ces derniers
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
DE602006014411D1
(de)
*
|
2005-07-27 |
2010-07-01 |
Boehringer Ingelheim Pharma |
Glucopyranosyl-substituierte ((hetero)cycloalyklethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters (sglt)
|
US20070027178A1
(en)
*
|
2005-07-28 |
2007-02-01 |
Bristol-Myers Squibb Company |
Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
JP5175191B2
(ja)
*
|
2005-08-30 |
2013-04-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
|
TW200745075A
(en)
*
|
2005-09-08 |
2007-12-16 |
Boehringer Ingelheim Int |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
AR056195A1
(es)
*
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
MY152172A
(en)
*
|
2005-12-28 |
2014-08-15 |
Takeda Pharmaceutical |
Therapeutic agent for diabetes
|
US7745414B2
(en)
|
2006-02-15 |
2010-06-29 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
|
PE20080697A1
(es)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
EA015687B1
(ru)
|
2006-05-04 |
2011-10-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Полиморфы
|
EP1852108A1
(fr)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Compositions d'inhibiteurs de la DPP IV
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
US20090176717A1
(en)
*
|
2006-06-01 |
2009-07-09 |
Glycomimetics, Inc. |
Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
US7919598B2
(en)
*
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
TWI418556B
(zh)
*
|
2006-07-27 |
2013-12-11 |
Mitsubishi Tanabe Pharma Corp |
吲哚衍生物
|
TWI403516B
(zh)
|
2006-07-27 |
2013-08-01 |
Chugai Pharmaceutical Co Ltd |
To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
|
TWI432446B
(zh)
|
2006-07-27 |
2014-04-01 |
Chugai Pharmaceutical Co Ltd |
稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
|
EP2054426A1
(fr)
|
2006-08-15 |
2009-05-06 |
Boehringer Ingelheim International GmbH |
Dérivés de cyclopropyl-benzène à substitution glucopyranosyle, compositions pharmaceutiques contenant de tels composés, leur utilisation en tant qu'inhibiteurs de sglt et leur procédé de fabrication
|
EP2097102B1
(fr)
*
|
2006-09-07 |
2012-05-30 |
GlaxoSmithKline Biologicals s.a. |
Vaccin combiné contre le virus de la polio comprenant une quantité réduite d'antigène
|
TWI499414B
(zh)
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
|
US20080194575A1
(en)
*
|
2006-10-04 |
2008-08-14 |
Naiara Beraza |
Treatment for non-alcoholic-steatohepatitis
|
BRPI0719523A2
(pt)
*
|
2006-10-13 |
2015-06-16 |
Chugai Pharmaceutical Co Ltd |
Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes
|
JP2010507629A
(ja)
|
2006-10-27 |
2010-03-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
4−(β−D−グルコピラノス−1−イル)−1−メチル−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)−ベンジル]−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用
|
UY30730A1
(es)
*
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
NZ577391A
(en)
*
|
2006-12-04 |
2011-11-25 |
Janssen Pharmaceutica Nv |
Thienyl-containing glycopyranosyl derivatives as antidiabetics
|
MX2009005935A
(es)
|
2006-12-06 |
2009-06-30 |
Smithkline Beecham Corp |
Compuestos biciclicos y su uso como anti-diabeticos.
|
WO2008075736A1
(fr)
*
|
2006-12-21 |
2008-06-26 |
Astellas Pharma Inc. |
Procédé de fabrication d'un dérivé de c-glycoside et intermédiaire de synthèse de celui-ci
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
WO2008109591A1
(fr)
*
|
2007-03-08 |
2008-09-12 |
Lexicon Pharmaceuticals, Inc. |
Analogues de phlorizine utilisés comme inhibiteurs du co-transporteur 2 du sodium-glucose
|
TW200904454A
(en)
*
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
|
AU2014201239B2
(en)
*
|
2007-03-22 |
2016-03-10 |
Astrazeneca Ab |
Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
|
PE20090185A1
(es)
*
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EP2998314B1
(fr)
|
2007-06-04 |
2020-01-22 |
Bausch Health Ireland Limited |
Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
|
US8026347B2
(en)
*
|
2007-07-26 |
2011-09-27 |
Lexicon Pharmaceuticals, Inc. |
Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
|
PE20090938A1
(es)
*
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
PE20090603A1
(es)
*
|
2007-08-16 |
2009-06-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
|
US20110112069A1
(en)
*
|
2007-08-17 |
2011-05-12 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
CN101790311B
(zh)
*
|
2007-08-23 |
2014-04-23 |
泰拉科斯有限公司 |
苄基苯衍生物及使用方法
|
ME03072B
(fr)
*
|
2007-09-10 |
2019-01-20 |
Janssen Pharmaceutica Nv |
Procédé pour la préparation de composés utiles en tant qu'inhibiteurs de sglt
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
CA2706018C
(fr)
*
|
2007-11-30 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Derives de 1,5-dihydro-pyrazolo(3,4-d)pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a pour le traitement de troubles du snc
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
CN104387354A
(zh)
*
|
2007-12-27 |
2015-03-04 |
阿斯利康公司 |
Sglt2 抑制剂的晶体结构及其制备方法
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
WO2009096455A1
(fr)
|
2008-01-31 |
2009-08-06 |
Astellas Pharma Inc. |
Composition pharmaceutique pour le traitement de stéatoses hépatiques
|
CN101503399B
(zh)
*
|
2008-02-04 |
2012-06-27 |
白鹭医药技术(上海)有限公司 |
C-芳基葡萄糖苷sglt2抑制剂
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
PE20091730A1
(es)
*
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
US8791077B2
(en)
*
|
2008-05-22 |
2014-07-29 |
Astrazeneca Ab |
Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
|
WO2009143021A1
(fr)
*
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Procédé pour traiter et prévenir des calculs rénaux à l'aide d'un inhibiteur de sglt2 et composition le contenant
|
US8518895B2
(en)
|
2008-05-22 |
2013-08-27 |
Bristol-Myers Squibb Company |
Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
EP3239170B1
(fr)
|
2008-06-04 |
2019-03-20 |
Synergy Pharmaceuticals Inc. |
Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
|
US9061060B2
(en)
*
|
2008-07-15 |
2015-06-23 |
Theracos Inc. |
Deuterated benzylbenzene derivatives and methods of use
|
WO2010009319A2
(fr)
|
2008-07-16 |
2010-01-21 |
Synergy Pharmaceuticals Inc. |
Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
MX2011001525A
(es)
*
|
2008-08-15 |
2011-03-29 |
Boehringer Ingelheim Int |
Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
|
CN102177147A
(zh)
*
|
2008-08-22 |
2011-09-07 |
泰拉科斯有限公司 |
制备sglt2抑制剂的方法
|
EA018492B1
(ru)
*
|
2008-08-28 |
2013-08-30 |
Пфайзер Инк. |
Диоксабицикло[3.2.1]октан-2,3,4-триольные производные
|
US9079905B2
(en)
|
2008-09-08 |
2015-07-14 |
Boehringer Ingelheim International Gmbh |
Compounds for the treatment of CNS disorders
|
MX2011002558A
(es)
|
2008-09-10 |
2011-04-26 |
Boehringer Ingelheim Int |
Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
|
EA201100502A1
(ru)
*
|
2008-09-19 |
2011-10-31 |
Новартис Аг |
Гликозидные производные и их применения
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
WO2010045656A2
(fr)
*
|
2008-10-17 |
2010-04-22 |
Nectid, Inc. |
Nouvelles formes posologiques d'inhibiteur sglt2
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
CA2745037C
(fr)
|
2008-12-23 |
2020-06-23 |
Boehringer Ingelheim International Gmbh |
Formes salines de 1-[(4-methyl-quinazoline-2-yl)methyl]-3-methyl-7-(2-butyne-1-yl)-8(3-(r)-amino-piperidine-1-yl)-xanthine
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
MA33043B1
(fr)
|
2009-02-13 |
2012-02-01 |
Boehringer Ingelheim Int |
Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie
|
EA024072B1
(ru)
|
2009-02-13 |
2016-08-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Фармацевтическая дозированная форма, включающая производное глюкопиранозилдифенилметана, и применения для улучшения гликемического контроля у пациентов
|
CN102307577A
(zh)
|
2009-02-13 |
2012-01-04 |
贝林格尔.英格海姆国际有限公司 |
包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
|
BRPI1008653A2
(pt)
*
|
2009-02-23 |
2016-03-08 |
Taisho Pharmaceutical Co Ltd |
compostos 4-isopropil fenil glicitol como inibidores de sglt1
|
EP2226076A1
(fr)
|
2009-02-25 |
2010-09-08 |
Henning Vollert |
Support d'enregistrement thermosensible et procédé d'enregistrement
|
MY156377A
(en)
*
|
2009-03-31 |
2016-02-15 |
Boehringer Ingelheim Int |
1-heterocycl-1, 5-dihydro-pyrazolo [3 , 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
CN102639125A
(zh)
*
|
2009-05-27 |
2012-08-15 |
百时美施贵宝公司 |
使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
ES2416459T3
(es)
|
2009-07-10 |
2013-08-01 |
Janssen Pharmaceutica, N.V. |
Procedimiento de cristalización para 1-( -D-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno
|
AR077859A1
(es)
*
|
2009-08-12 |
2011-09-28 |
Boehringer Ingelheim Int |
Compuestos para el tratamiento de trastornos del snc
|
MX2012002942A
(es)
*
|
2009-09-30 |
2012-04-11 |
Boehringer Ingelheim Int |
Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno.
|
WO2011039108A2
(fr)
|
2009-09-30 |
2011-04-07 |
Boehringer Ingelheim International Gmbh |
Procédés de préparation de dérivés de benzyl-benzène substitués par un glucopyranosyle
|
US10610489B2
(en)
*
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
JP5833011B2
(ja)
*
|
2009-10-14 |
2015-12-16 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Sglt2の阻害物質として有用な化合物の調製プロセス
|
US8163704B2
(en)
*
|
2009-10-20 |
2012-04-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
AU2010310956B2
(en)
|
2009-11-02 |
2014-05-08 |
Pfizer Inc. |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
RU2583920C2
(ru)
|
2009-11-13 |
2016-05-10 |
Астразенека Аб |
Композиция двухслойной таблетки
|
PL2498759T3
(pl)
|
2009-11-13 |
2019-03-29 |
Astrazeneca Ab |
Formulacje tabletek o natychmiastowym uwalnianiu
|
AU2010317842A1
(en)
|
2009-11-16 |
2012-07-12 |
Mellitech |
[1,5]-diazocin derivatives
|
CN107115530A
(zh)
|
2009-11-27 |
2017-09-01 |
勃林格殷格翰国际有限公司 |
基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
|
WO2011070592A2
(fr)
|
2009-12-09 |
2011-06-16 |
Panacea Biotec Ltd. |
Nouveaux dérivés de sucres
|
CN102134226B
(zh)
*
|
2010-01-26 |
2013-06-12 |
天津药物研究院 |
一类苯基c-葡萄糖苷衍生物、其制备方法和用途
|
WO2011107494A1
(fr)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
|
JP2013523681A
(ja)
*
|
2010-03-30 |
2013-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Sglt2インヒビター及びppar−ガンマアゴニストを含む医薬組成物並びにその使用
|
AU2011249722B2
(en)
|
2010-05-05 |
2015-09-17 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
CN105769792A
(zh)
|
2010-05-11 |
2016-07-20 |
田边三菱制药株式会社 |
含1-(β-D-吡喃葡糖基)-3-(苯基噻吩基甲基)苯化合物的片剂
|
DK2568988T3
(en)
|
2010-05-11 |
2016-08-22 |
Janssen Pharmaceutica Nv |
Pharmaceutical formulations comprising 1- (BETA-D-glucopyranosyl) -2-THIENYLMETHYLBENZEN derivatives as inhibitors of SGLT
|
WO2011153712A1
(fr)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène
|
KR20220025926A
(ko)
|
2010-06-24 |
2022-03-03 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
GEP20156217B
(en)
|
2010-08-12 |
2015-01-12 |
Boehringer Ingelheim Int |
6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
WO2012025857A1
(fr)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Dérivés de cycloalkyl méthoxybenzyl phényl pyrane en tant qu'inhibiteurs du cotransporteur de glucose sodium-dépendant (sglt2)
|
US20130224296A1
(en)
|
2010-09-03 |
2013-08-29 |
Bristol-Myers Squibb Company |
Drug Formulations Using Water Soluble Antioxidants
|
US8921328B2
(en)
|
2010-09-14 |
2014-12-30 |
Glycomimetics, Inc. |
E-selectin antagonists
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012041898A1
(fr)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète
|
CN102453026A
(zh)
|
2010-10-27 |
2012-05-16 |
上海艾力斯医药科技有限公司 |
C-芳基葡糖苷衍生物、制备方法及其应用
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
TWI631963B
(zh)
*
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
JP2014504639A
(ja)
|
2011-02-01 |
2014-02-24 |
ブリストル−マイヤーズ スクイブ カンパニー |
アミン化合物を含む医薬製剤
|
US20130035281A1
(en)
*
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
CN103965176B
(zh)
*
|
2011-02-18 |
2016-03-16 |
凯惠药业(上海)有限公司 |
一种芳基糖苷类化合物及其制备方法和应用
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
CN102167715B
(zh)
*
|
2011-03-07 |
2013-04-24 |
上海惠斯生物科技有限公司 |
一种钠-葡萄糖协同运转蛋白-2原料药的共晶制备方法
|
ES2586846T3
(es)
|
2011-04-13 |
2016-10-19 |
Janssen Pharmaceutica, N.V. |
Proceso de preparación de compuestos útiles como inhibidores de SGLT2
|
US8957033B2
(en)
*
|
2011-04-25 |
2015-02-17 |
Beijing Prelude Pharm. Sci. & Tech. Co., Ltd. |
Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
|
US9035044B2
(en)
|
2011-05-09 |
2015-05-19 |
Janssen Pharmaceutica Nv |
L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
|
MX2013013734A
(es)
*
|
2011-05-26 |
2014-02-27 |
Tfchem |
Familia de carba-azucares de arilo, heteroarilo, o-arilo y o-heteroarilo.
|
EP2529742B1
(fr)
|
2011-06-03 |
2013-11-20 |
ratiopharm GmbH |
Composition pharmaceutique comportant de la dapagliflozine et cyclodextrine
|
CA2837232A1
(fr)
|
2011-06-03 |
2012-12-06 |
Ratiopharm Gmbh |
Composition pharmaceutique comprenant de la dapagliflozine et de la cyclodextrine
|
JP5835598B2
(ja)
|
2011-06-03 |
2015-12-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
神経弛緩剤で治療されている患者において代謝性障害を治療するためのsglt−2阻害剤
|
CN102875503B
(zh)
|
2011-06-25 |
2016-05-25 |
山东轩竹医药科技有限公司 |
C-糖苷衍生物
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
KR101985384B1
(ko)
|
2011-07-15 |
2019-06-03 |
베링거 인겔하임 인터내셔날 게엠베하 |
치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
|
WO2013038429A2
(fr)
|
2011-09-13 |
2013-03-21 |
Panacea Biotec Ltd. |
Nouveaux inhibiteurs de sglt
|
KR20140097258A
(ko)
*
|
2011-10-31 |
2014-08-06 |
시노팜 타이완 리미티드 |
Sglt2 억제제의 결정성 및 비-결정성 형태
|
EP2597090A1
(fr)
*
|
2011-11-28 |
2013-05-29 |
Sandoz AG |
Hydrate de dapagliflozine cristalline
|
AU2012358150B2
(en)
|
2011-12-22 |
2017-07-20 |
Glycomimetics, Inc. |
E-selectin antagonist compounds, compositions, and methods of use
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
EP2849755A1
(fr)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
|
WO2013174767A1
(fr)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
|
CN103450214B
(zh)
*
|
2012-05-29 |
2016-04-06 |
广东东阳光药业有限公司 |
吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
|
EP2679229B1
(fr)
|
2012-06-30 |
2019-02-27 |
BioActive Food GmbH |
Composition pour le traitement de pathologies hyperglycémiques
|
CA2883118A1
(fr)
*
|
2012-08-30 |
2014-03-06 |
Taisho Pharmaceutical Co., Ltd. |
Association d'un inhibiteur du sglt2 et d'un antihypertenseur
|
ES2668045T3
(es)
|
2012-12-07 |
2018-05-16 |
Glycomimetics, Inc. |
Compuestos, composiciones y métodos que usan antagonistas de la E-selectina para la movilización de las células hematopoyéticas
|
CN103910769B
(zh)
|
2012-12-31 |
2018-10-02 |
上海璎黎药业有限公司 |
葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
|
EP2774619B1
(fr)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Composition pour le traitement de pathologies hyperglycémiques
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
ES2740299T3
(es)
|
2013-03-14 |
2020-02-05 |
Msd Int Gmbh |
Métodos para preparar inhibidores de SGLT2
|
CA2905438A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonistes de la guanylate cyclase et leurs utilisations
|
CA2905435A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions utiles pour le traitement de troubles gastro-intestinaux
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
PT2981269T
(pt)
|
2013-04-04 |
2023-10-10 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamento de distúrbios metabólicos em animais equinos
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
PT2981271T
(pt)
|
2013-04-05 |
2019-02-19 |
Boehringer Ingelheim Int |
Utilizações terapêuticas de empagliflozina
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
PL2986304T3
(pl)
|
2013-04-18 |
2022-05-02 |
Boehringer Ingelheim International Gmbh |
Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
|
EP2991999B1
(fr)
|
2013-04-29 |
2019-05-08 |
Mapi Pharma Limited |
Co-cristal de dapagliflozine et de lactose
|
AU2014274812B2
(en)
|
2013-06-05 |
2018-09-27 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
US20160214953A1
(en)
|
2013-09-23 |
2016-07-28 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of dapagliflozin
|
ES2605886T3
(es)
|
2013-09-27 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Derivados de glucopiranosilo y sus usos en medicina
|
US20160237054A1
(en)
*
|
2013-09-27 |
2016-08-18 |
Sun Pharmaceutical Industries Limited |
Process for the purification of dapagliflozin
|
CN105611920B
(zh)
|
2013-10-12 |
2021-07-16 |
泰拉科斯萨普有限责任公司 |
羟基-二苯甲烷衍生物的制备
|
US20160280619A1
(en)
*
|
2013-10-31 |
2016-09-29 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
|
AU2014364999B2
(en)
|
2013-12-17 |
2019-12-12 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in feline animals
|
US9902751B2
(en)
|
2013-12-30 |
2018-02-27 |
Mylan Laboratories Limited |
Process for the preparation of empagliflozin
|
US9315438B2
(en)
|
2014-01-03 |
2016-04-19 |
Xuanzhu Pharma Co., Ltd |
Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
|
CN106349201B
(zh)
*
|
2014-01-03 |
2018-09-18 |
山东轩竹医药科技有限公司 |
光学纯的苄基-4-氯苯基的c-糖苷衍生物
|
CN103739581B
(zh)
*
|
2014-01-23 |
2016-11-23 |
中国药科大学 |
C-芳基葡萄糖苷sglt2抑制剂
|
KR102414283B1
(ko)
|
2014-01-23 |
2022-06-29 |
베링거잉겔하임베트메디카게엠베하 |
개과 동물에서 대사 장애의 치료
|
CN104829572B
(zh)
*
|
2014-02-10 |
2019-01-04 |
江苏豪森药业集团有限公司 |
达格列净新晶型及其制备方法
|
IN2014MU00626A
(fr)
*
|
2014-02-21 |
2015-09-25 |
Cadila Healthcare Ltd |
|
JP6615109B2
(ja)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dpp−4阻害薬の医学的使用
|
EP3110402A1
(fr)
|
2014-02-28 |
2017-01-04 |
Sun Pharmaceutical Industries Ltd |
Compositions de dapagliflozin
|
IN2014CH01141A
(fr)
*
|
2014-03-06 |
2015-09-11 |
Msn Lab Private Ltd |
|
MX2016012705A
(es)
|
2014-04-01 |
2016-12-16 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamiento de trastornos metabolicos en animales equinos.
|
CN105001213B
(zh)
*
|
2014-04-14 |
2020-08-28 |
上海迪诺医药科技有限公司 |
C-芳基糖苷衍生物、其药物组合物、制备方法及应用
|
EP2944311A1
(fr)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Combinaison de substances biologiques actives destinée au traitement de pathologies hypoglycémiques
|
CN106714796A
(zh)
*
|
2014-05-16 |
2017-05-24 |
阿斯利康(瑞典)有限公司 |
用于抑制sglt2抑制剂的胰高血糖素分泌的方法
|
WO2015198227A1
(fr)
|
2014-06-23 |
2015-12-30 |
Sun Pharmaceutical Industries Limited |
Co-cristal de dapagliflozin et d'acide citrique
|
MX2017003944A
(es)
|
2014-09-25 |
2017-06-26 |
Astrazeneca Ab |
Combinacion de un acido graso omega-3 y un inhibidor de sglt-2 para tratar enfermedades hepaticas.
|
CN104327027B
(zh)
*
|
2014-10-14 |
2017-04-05 |
中国药科大学 |
一类新型c‑芳基葡萄糖苷sglt2抑制剂
|
CN104478839A
(zh)
*
|
2014-11-24 |
2015-04-01 |
苏州乔纳森新材料科技有限公司 |
一种达格列净的合成方法
|
CN104496952B
(zh)
*
|
2014-11-28 |
2017-04-19 |
深圳翰宇药业股份有限公司 |
一种达格列净的合成方法
|
PL3227310T3
(pl)
|
2014-12-03 |
2020-02-28 |
Glycomimetics, Inc. |
Heterodwufunkcyjne inhibitory selektyn E i receptorów chemokinowych CXCR4”
|
CN105753910A
(zh)
*
|
2014-12-16 |
2016-07-13 |
康普药业股份有限公司 |
一种卡格列净中间体的制备方法
|
CN104529970A
(zh)
*
|
2015-01-08 |
2015-04-22 |
江苏联环药业股份有限公司 |
制备达格列净的方法
|
CN104478959A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途
|
CN104478957A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478968A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104478966A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104530149A
(zh)
*
|
2015-01-14 |
2015-04-22 |
佛山市赛维斯医药科技有限公司 |
卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478965A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一类烷氧基苯基s-葡萄糖苷衍生物、其制备方法和用途
|
CN104497070A
(zh)
*
|
2015-01-15 |
2015-04-08 |
佛山市赛维斯医药科技有限公司 |
一种含三氟甲基苯s-葡萄糖苷结构的化合物和用途
|
CN104478963A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯s-葡萄糖苷结构的化合物及其用途
|
EP3256482B1
(fr)
|
2015-02-09 |
2019-11-27 |
Indoco Remedies Limited |
Procédé de préparation de composés inhibiteurs de sglt
|
KR20180006881A
(ko)
|
2015-03-09 |
2018-01-19 |
인테크린 테라퓨틱스, 아이엔씨. |
비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
|
WO2016161995A1
(fr)
|
2015-04-08 |
2016-10-13 |
Zentiva, K.S. |
Formes solides de dapagliflozine amorphe
|
US10556877B2
(en)
|
2015-05-05 |
2020-02-11 |
Glenmark Life Sciences Limited |
Process for preparation of dapagliflozin
|
CN106317068A
(zh)
*
|
2015-06-23 |
2017-01-11 |
中国科学院上海药物研究所 |
一种c,o-螺环芳基糖苷类化合物及其制备和应用
|
CN104961715B
(zh)
*
|
2015-07-10 |
2017-08-22 |
浙江美诺华药物化学有限公司 |
一种达格列净的制备方法
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
WO2017046730A1
(fr)
|
2015-09-15 |
2017-03-23 |
Laurus Labs Private Limited |
Co-cristaux d'inhibiteurs de sglt2, procédé pour leur préparation et compositions pharmaceutiques de ceux-ci
|
CZ2015729A3
(cs)
|
2015-10-13 |
2017-04-26 |
Zentiva, K.S. |
Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
|
CN105218329B
(zh)
*
|
2015-10-15 |
2017-05-03 |
上海应用技术学院 |
一种列净类似物中间体及其制备方法
|
JP2018530592A
(ja)
|
2015-10-15 |
2018-10-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
代謝性ミオパチーの治療に使用するためのsglt−2阻害剤
|
US9845303B2
(en)
|
2015-10-19 |
2017-12-19 |
Cadila Healthcare Limited |
Process for the preparation of dapagliflozin
|
CN106892929B
(zh)
*
|
2015-12-17 |
2020-01-14 |
上海艾力斯医药科技有限公司 |
螺缩酮衍生物及其制备方法和应用
|
CN105693669A
(zh)
*
|
2015-12-28 |
2016-06-22 |
南昌大学 |
一种抗糖尿病化合物及其制备方法和用途
|
BR112018013408B1
(pt)
*
|
2016-01-04 |
2024-01-30 |
Je Il Pharmaceutical Co., Ltd |
Derivados de c-glicosídeo que têm anel fenila fusionado ou sais farmaceuticamente aceitáveis dos mesmos, método para preparar os mesmos e composição farmacêutica compreendendo os mesmos
|
WO2017118945A1
(fr)
|
2016-01-08 |
2017-07-13 |
Lupin Limited |
Prémélange de dapagliflozine et son procédé de préparation
|
WO2017127422A1
(fr)
|
2016-01-22 |
2017-07-27 |
Glycomimetics, Inc. |
Inhibiteurs glycomimétiques des lectines pa-il et pa-iil
|
US9834533B2
(en)
*
|
2016-02-19 |
2017-12-05 |
Scinopharm Taiwan, Ltd. |
Process for preparing SGLT2 inhibitors and intermediates thereof
|
WO2017151708A1
(fr)
|
2016-03-02 |
2017-09-08 |
Glycomimetics, Inc. |
Méthodes pour le traitement et/ou à la prévention de maladies cardiovasculaires par inhibition de la sélectine e
|
BR112018069782A2
(pt)
|
2016-03-31 |
2019-01-29 |
Lupin Ltd |
composição farmacêutica de dapagliflozina
|
CN107304194A
(zh)
*
|
2016-04-20 |
2017-10-31 |
扬子江药业集团上海海尼药业有限公司 |
制备达格列净的方法
|
JP7007300B2
(ja)
*
|
2016-05-24 |
2022-01-24 |
江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 |
ダパグリフロジンの新規な結晶形並びにその製造方法および用途
|
WO2017203229A1
(fr)
|
2016-05-27 |
2017-11-30 |
Cipla Limited |
Prémélanges de dapagliflozine
|
CA3022202A1
(fr)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinaisons de linagliptine et de metformine
|
WO2018002673A1
(fr)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
|
WO2018031445A1
(fr)
|
2016-08-08 |
2018-02-15 |
Glycomimetics, Inc. |
Combinaison d'inhibiteurs des points de contrôle des lymphocytes t avec des inhibiteurs de e-sélectine ou de cxcr4, ou avec des inhibiteurs hétérobifonctionnels de e-sélectine et de cxcr4
|
EP3497090B1
(fr)
*
|
2016-08-09 |
2022-08-03 |
Laurus Labs Limited |
Nouveaux procédés de préparation de dapagliflozine ou de ses solvates ou co-cristaux de celle-ci
|
WO2018029264A1
(fr)
|
2016-08-10 |
2018-02-15 |
Amneal Pharmaceuticals Company Gmbh |
Procédé de préparation de dapagliflozine et de ses intermédiaires
|
KR102607640B1
(ko)
|
2016-10-07 |
2023-11-28 |
글리코미메틱스, 인크. |
매우 강력한 다량체성 e-셀렉틴 길항물질
|
EA201990951A1
(ru)
|
2016-10-19 |
2019-11-29 |
|
Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
|
KR20180058510A
(ko)
|
2016-11-24 |
2018-06-01 |
한미약품 주식회사 |
다파글리플로진 l-프롤린을 포함하는 약제학적 제제
|
CN108218928B
(zh)
*
|
2016-12-13 |
2020-06-30 |
华润双鹤药业股份有限公司 |
葡萄糖苷的二环衍生物及其制备方法和用途
|
WO2018142422A1
(fr)
*
|
2017-02-02 |
2018-08-09 |
Indoco Remedies Limited |
Procédé de préparation de dapagliflozine
|
EP3596096A1
(fr)
|
2017-03-15 |
2020-01-22 |
GlycoMimetics, Inc. |
Dérivés de galactopyranosyle-cyclohexyle utilisés en tant qu'antagonistes d'e-sélectine
|
WO2018167589A1
(fr)
|
2017-03-16 |
2018-09-20 |
Inventia Healthcare Private Limited |
Composition pharmaceutique comprenant de la dapagliflozine
|
AU2018249822A1
(en)
|
2017-04-03 |
2019-10-31 |
Coherus Biosciences Inc. |
PPArgamma agonist for treatment of progressive supranuclear palsy
|
CN110869380A
(zh)
|
2017-05-09 |
2020-03-06 |
皮拉马尔企业有限公司 |
用于制备sglt2抑制剂和其中间体的方法
|
TWI797133B
(zh)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
用於經口投予的固體組成物
|
KR101943382B1
(ko)
|
2017-09-19 |
2019-01-29 |
오토텔릭바이오 주식회사 |
Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
|
JP7275131B2
(ja)
|
2017-11-30 |
2023-05-17 |
グリコミメティクス, インコーポレイテッド |
骨髄浸潤リンパ球を動員する方法、およびその使用
|
BR112020013198A2
(pt)
|
2017-12-29 |
2020-12-01 |
Glycomimetics, Inc. |
inibidores heterobifuncionais de e-selectina e galectina-3
|
WO2019173229A1
(fr)
|
2018-03-05 |
2019-09-12 |
Glycomimetics, Inc. |
Méthodes de traitement de la leucémie aiguë myéloïde et d'états pathologiques associés
|
EP3781166A1
(fr)
|
2018-04-17 |
2021-02-24 |
Boehringer Ingelheim International GmbH |
Composition pharmaceutique, méthodes de traitement et utilisations associées
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
WO2020001812A1
(fr)
|
2018-06-25 |
2020-01-02 |
Pharmathen S.A. |
Nouveau procédé de préparation d'inhibiteurs de sglt-2
|
KR20200005320A
(ko)
|
2018-07-06 |
2020-01-15 |
한미약품 주식회사 |
무정형의 다파글리플로진 l-프롤린을 포함하는 약학적 제제 및 이의 제조방법
|
BR112021000139A2
(pt)
*
|
2018-07-19 |
2021-04-06 |
Astrazeneca Ab |
Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
|
WO2020039394A1
(fr)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
Nouvelles combinaisons de médicaments
|
KR102131359B1
(ko)
|
2018-09-07 |
2020-07-07 |
오토텔릭바이오 주식회사 |
안정성이 향상된 의약 조성물
|
CN109705075B
(zh)
*
|
2018-12-13 |
2022-12-23 |
苏中药业集团股份有限公司 |
一种达格列净的纯化方法
|
WO2020139962A1
(fr)
|
2018-12-27 |
2020-07-02 |
Glycomimetics, Inc. |
Inhibiteurs hétérobifonctionnels d'e-sélectine et de galectine-3
|
JP2022530575A
(ja)
|
2019-08-30 |
2022-06-30 |
アストラゼネカ・アクチエボラーグ |
ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
|
AU2020394498A1
(en)
|
2019-11-28 |
2022-06-09 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors in the drying-off of non-human mammals
|
BR112022016360A2
(pt)
|
2020-02-17 |
2022-10-04 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
|
CA3169665A1
(fr)
|
2020-02-21 |
2021-08-26 |
Zaklady Farmaceutyczne Polpharma S.A. |
Composition pharmaceutique comprenant de la dapagliflozine
|
WO2021176096A1
(fr)
|
2020-03-05 |
2021-09-10 |
Krka, D.D., Novo Mesto |
Composition pharmaceutique comprenant un inhibiteur du sglt2
|
JP2023515668A
(ja)
|
2020-03-06 |
2023-04-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Apol-1依存性巣状分節性糸球体硬化症を治療する方法
|
US20230201174A1
(en)
|
2020-04-22 |
2023-06-29 |
Bayer Aktiengesellschaft |
Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
|
WO2021219691A1
(fr)
|
2020-04-29 |
2021-11-04 |
Astrazeneca Ab |
Dapagliflozine et ambrisentan pour la prévention et le traitement de la covid-19
|
EP4161912A1
(fr)
|
2020-06-05 |
2023-04-12 |
KRKA, d.d., Novo mesto |
Préparation de dapagliflozine amorphe très pure
|
WO2021260617A1
(fr)
*
|
2020-06-25 |
2021-12-30 |
Hikal Limited |
Procédé amélioré de préparation de monohydrate de dapagliflozine-propanediol
|
MX2023000276A
(es)
|
2020-07-10 |
2023-02-09 |
Astrazeneca Ab |
Combinacion de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal cronica.
|
US20220023252A1
(en)
|
2020-07-27 |
2022-01-27 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
WO2022051316A1
(fr)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Combinaisons à dose fixe de chs-131 et d'un inhibiteur de sglt-2
|
EP4206212A1
(fr)
|
2020-09-30 |
2023-07-05 |
Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. |
Cocristal d'inhibiteur de sglt-2 et de sarcosine, procédé pour sa préparation et utilisation correspondante
|
WO2022119543A1
(fr)
|
2020-12-03 |
2022-06-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Procédé de préparation de comprimés comprenant de la dapagliflozine amorphe et du chlorhydrate de metformine
|
TR202019592A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Amorf dapagliflozinin katı farmasötik formülasyonları
|
TR202019590A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
|
TR202019589A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür i̇çeren fi̇lm kapli tablet formülasyonu
|
AU2022251165A1
(en)
|
2021-04-01 |
2023-11-09 |
Astrazeneca Uk Limited |
Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
|
EP4079296A1
(fr)
|
2021-04-21 |
2022-10-26 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Formulation de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
|
WO2023006745A1
(fr)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de l'hypertension chez des mammifères non humains
|
WO2023006718A1
(fr)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de maladies cardiaques chez des mammifères non humains à l'exclusion de félins, en particulier des canidés
|
KR20240040106A
(ko)
|
2021-07-28 |
2024-03-27 |
베링거잉겔하임베트메디카게엠베하 |
비-사람 포유류에서 신장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
|
CN113773194B
(zh)
|
2021-08-16 |
2023-05-02 |
浙江奥翔药业股份有限公司 |
作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
|
WO2023129595A1
(fr)
|
2021-12-30 |
2023-07-06 |
Newamsterdam Pharma B.V. |
Combinaison d'obicetrapib et d'inhibiteur de sglt2
|
EP4212150A1
(fr)
|
2022-01-13 |
2023-07-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Composition de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
|
WO2023144722A1
(fr)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozine destinée à être utilisée dans le traitement du prédiabète ou pour réduire le risque de développer un diabète de type 2
|
WO2023227492A1
(fr)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Compositions pharmaceutiques aqueuses comprenant des inhibiteurs de sglt-2
|
WO2023237512A1
(fr)
|
2022-06-07 |
2023-12-14 |
Astrazeneca Ab |
Combinaisons de modulateurs de rxfp1 et d'inhibiteurs de sglt2
|
KR102490653B1
(ko)
*
|
2022-08-03 |
2023-01-20 |
진양제약주식회사 |
다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
|
KR20240028315A
(ko)
|
2022-08-24 |
2024-03-05 |
주식회사 제뉴원사이언스 |
다파글리플로진, 시타글립틴, 및 메트포르민을 함유하는 복합 제제
|